PharmaEssentia wins Health Canada approval for BESREMi in polycythemia vera
Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.
Pharma & Biotech
Pharma & Biotech
FDA approves BESREMi Pen as PharmaEssentia targets easier long-term polycythemia vera treatment
FDA approval brings BESREMi Pen to U.S. polycythemia vera care. Find out how convenience, safety and access may shape adoption.
Pharma & Biotech
Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.
Pharma & Biotech
PharmaEssentia expands beyond Taiwan with Puerto Rico plant as BESREMi growth plans widen
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
Pharma & Biotech
PharmaEssentia Corporation secures Japan approval for high-dose BESREMi regimen in polycythemia vera
Japan approves high-dose BESREMi regimen for polycythemia vera. Read the full analysis on safety, adoption, and what clinicians will watch next.